Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

SOD2 acetylation on lysine 68 promotes stem cell reprogramming in breast cancer.

He C, Danes JM, Hart PC, Zhu Y, Huang Y, de Abreu AL, O'Brien J, Mathison AJ, Tang B, Frasor JM, Wakefield LM, Ganini D, Stauder E, Zielonka J, Gantner BN, Urrutia RA, Gius D, Bonini MG.

Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23534-23541. doi: 10.1073/pnas.1902308116. Epub 2019 Oct 7.

PMID:
31591207
2.

The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models In Vivo Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ.

Yang Y, Yang HH, Tang B, Wu AML, Flanders KC, Moshkovich N, Weinberg DS, Welsh MA, Weng J, Ochoa HJ, Hu TY, Herrmann MA, Chen J, Edmondson EF, Simpson RM, Liu F, Liu H, Lee MP, Wakefield LM.

Clin Cancer Res. 2020 Feb 1;26(3):643-656. doi: 10.1158/1078-0432.CCR-19-2370. Epub 2019 Oct 3.

PMID:
31582516
3.

Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein.

Byun JS, Park S, Yi DI, Shin JH, Hernandez SG, Hewitt SM, Nicklaus MC, Peach ML, Guasch L, Tang B, Wakefield LM, Yan T, Caban A, Jones A, Kabbout M, Vohra N, Nápoles AM, Singhal S, Yancey R, De Siervi A, Gardner K.

Cell Death Dis. 2019 Sep 18;10(10):689. doi: 10.1038/s41419-019-1892-7.

4.

The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription.

Malik N, Yan H, Moshkovich N, Palangat M, Yang H, Sanchez V, Cai Z, Peat TJ, Jiang S, Liu C, Lee M, Mock BA, Yuspa SH, Larson D, Wakefield LM, Huang J.

Nat Commun. 2019 May 6;10(1):2071. doi: 10.1038/s41467-019-10102-6.

5.

Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to Matrin 3.

Chaudhary R, Gryder B, Woods WS, Subramanian M, Jones MF, Li XL, Jenkins LM, Shabalina SA, Mo M, Dasso M, Yang Y, Wakefield LM, Zhu Y, Frier SM, Moriarity BS, Prasanth KV, Perez-Pinera P, Lal A.

Elife. 2017 Jun 5;6. pii: e23244. doi: 10.7554/eLife.23244.

6.

Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis.

Yang Y, Yang HH, Hu Y, Watson PH, Liu H, Geiger TR, Anver MR, Haines DC, Martin P, Green JE, Lee MP, Hunter KW, Wakefield LM.

Oncotarget. 2017 May 9;8(19):30621-30643. doi: 10.18632/oncotarget.15695.

7.

Quantitation of TGF-β proteins in mouse tissues shows reciprocal changes in TGF-β1 and TGF-β3 in normal vs neoplastic mammary epithelium.

Flanders KC, Yang YA, Herrmann M, Chen J, Mendoza N, Mirza AM, Wakefield LM.

Oncotarget. 2016 Jun 21;7(25):38164-38179. doi: 10.18632/oncotarget.9416.

8.

Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.

Keysar SB, Le PN, Miller B, Jackson BC, Eagles JR, Nieto C, Kim J, Tang B, Glogowska MJ, Morton JJ, Padilla-Just N, Gomez K, Warnock E, Reisinger J, Arcaroli JJ, Messersmith WA, Wakefield LM, Gao D, Tan AC, Serracino H, Vasiliou V, Roop DR, Wang XJ, Jimeno A.

J Natl Cancer Inst. 2016 Sep 15;109(1). doi: 10.1093/jnci/djw189. Print 2017 Jan.

9.

Immune-mediated pathology in Duchenne muscular dystrophy.

Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, Wakefield LM, Woodcock J.

Sci Transl Med. 2015 Aug 5;7(299):299rv4. doi: 10.1126/scitranslmed.aaa7322. Review.

10.

Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics.

Chen JQ, Wakefield LM, Goldstein DJ.

J Transl Med. 2015 Jun 6;13:182. doi: 10.1186/s12967-015-0537-6. Review.

11.

Differential Proteome Analysis Identifies TGF-β-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer Model.

Sato M, Matsubara T, Adachi J, Hashimoto Y, Fukamizu K, Kishida M, Yang YA, Wakefield LM, Tomonaga T.

PLoS One. 2015 May 18;10(5):e0126483. doi: 10.1371/journal.pone.0126483. eCollection 2015.

12.

Growth differentiation factor-15 encodes a novel microRNA 3189 that functions as a potent regulator of cell death.

Jones MF, Li XL, Subramanian M, Shabalina SA, Hara T, Zhu Y, Huang J, Yang Y, Wakefield LM, Prasanth KV, Lal A.

Cell Death Differ. 2015 Oct;22(10):1641-53. doi: 10.1038/cdd.2015.9. Epub 2015 Feb 20.

13.

A flexible reporter system for direct observation and isolation of cancer stem cells.

Tang B, Raviv A, Esposito D, Flanders KC, Daniel C, Nghiem BT, Garfield S, Lim L, Mannan P, Robles AI, Smith WI Jr, Zimmerberg J, Ravin R, Wakefield LM.

Stem Cell Reports. 2015 Jan 13;4(1):155-169. doi: 10.1016/j.stemcr.2014.11.002. Epub 2014 Dec 11.

14.

Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells.

Hara T, Jones MF, Subramanian M, Li XL, Ou O, Zhu Y, Yang Y, Wakefield LM, Hussain SP, Gaedcke J, Ried T, Luo J, Caplen NJ, Lal A.

Oncotarget. 2014 Sep 15;5(17):7635-50.

15.

Definition of smad3 phosphorylation events that affect malignant and metastatic behaviors in breast cancer cells.

Bae E, Sato M, Kim RJ, Kwak MK, Naka K, Gim J, Kadota M, Tang B, Flanders KC, Kim TA, Leem SH, Park T, Liu F, Wakefield LM, Kim SJ, Ooshima A.

Cancer Res. 2014 Nov 1;74(21):6139-49. doi: 10.1158/0008-5472.CAN-14-0803. Epub 2014 Sep 9.

16.

Brightfield proximity ligation assay reveals both canonical and mixed transforming growth factor-β/bone morphogenetic protein Smad signaling complexes in tissue sections.

Flanders KC, Heger CD, Conway C, Tang B, Sato M, Dengler SL, Goldsmith PK, Hewitt SM, Wakefield LM.

J Histochem Cytochem. 2014 Dec;62(12):846-63. doi: 10.1369/0022155414550163. Epub 2014 Aug 20.

17.

Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide.

Chen X, Wakefield LM, Oppenheim JJ.

Oncoimmunology. 2014 Apr 16;3:e28247. eCollection 2014.

18.

An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer.

Sato M, Kadota M, Tang B, Yang HH, Yang YA, Shan M, Weng J, Welsh MA, Flanders KC, Nagano Y, Michalowski AM, Clifford RJ, Lee MP, Wakefield LM.

Breast Cancer Res. 2014 Jun 2;16(3):R57. doi: 10.1186/bcr3668.

19.

A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis.

Subramanian M, Francis P, Bilke S, Li XL, Hara T, Lu X, Jones MF, Walker RL, Zhu Y, Pineda M, Lee C, Varanasi L, Yang Y, Martinez LA, Luo J, Ambs S, Sharma S, Wakefield LM, Meltzer PS, Lal A.

Oncogene. 2015 Feb 26;34(9):1094-104. doi: 10.1038/onc.2014.46. Epub 2014 Mar 24.

20.

Pillars Article: production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986. 163: 1037-1050.

Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS.

J Immunol. 2014 Apr 1;192(7):2939-52. No abstract available.

21.

Nicotine exposure during differentiation causes inhibition of N-myc expression.

Ben-Yehudah A, Campanaro BM, Wakefield LM, Kinney TN, Brekosky J, Eisinger VM, Castro CA, Carlisle DL.

Respir Res. 2013 Nov 5;14:119. doi: 10.1186/1465-9921-14-119.

22.

Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer.

Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, Wakefield LM, Oppenheim JJ.

PLoS One. 2014 Jan 9;9(1):e85398. doi: 10.1371/journal.pone.0085398. eCollection 2014.

23.

A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster.

Li XL, Hara T, Choi Y, Subramanian M, Francis P, Bilke S, Walker RL, Pineda M, Zhu Y, Yang Y, Luo J, Wakefield LM, Brabletz T, Park BH, Sharma S, Chowdhury D, Meltzer PS, Lal A.

Mol Cell Biol. 2014 Feb;34(3):533-50. doi: 10.1128/MCB.01043-13. Epub 2013 Nov 25.

24.

Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects.

Luger D, Yang YA, Raviv A, Weinberg D, Banerjee S, Lee MJ, Trepel J, Yang L, Wakefield LM.

PLoS One. 2013 Oct 16;8(10):e76115. doi: 10.1371/journal.pone.0076115. eCollection 2013.

25.

Genetic background may contribute to PAM50 gene expression breast cancer subtype assignments.

Hu Y, Bai L, Geiger T, Goldberger N, Walker RC, Green JE, Wakefield LM, Hunter KW.

PLoS One. 2013 Aug 28;8(8):e72287. doi: 10.1371/journal.pone.0072287. eCollection 2013.

26.

Beyond TGFβ: roles of other TGFβ superfamily members in cancer.

Wakefield LM, Hill CS.

Nat Rev Cancer. 2013 May;13(5):328-41. doi: 10.1038/nrc3500. Review.

PMID:
23612460
27.

SDF-1α mediates wound-promoted tumor growth in a syngeneic orthotopic mouse model of breast cancer.

Stuelten CH, Cervoni-Curet FN, Busch JI, Sutton E, Webster JD, Kavalukas SL, Wakefield LM, Barbul A, Niederhuber JE.

PLoS One. 2013 Apr 11;8(4):e60919. doi: 10.1371/journal.pone.0060919. Print 2013.

28.

TGF-β-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury.

Matsubara T, Tanaka N, Sato M, Kang DW, Krausz KW, Flanders KC, Ikeda K, Luecke H, Wakefield LM, Gonzalez FJ.

J Lipid Res. 2012 Dec;53(12):2698-707. doi: 10.1194/jlr.M031773. Epub 2012 Oct 3.

29.

Biological responses to TGF-β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression.

Kohn EA, Yang YA, Du Z, Nagano Y, Van Schyndle CM, Herrmann MA, Heldman M, Chen JQ, Stuelten CH, Flanders KC, Wakefield LM.

Mol Cancer Res. 2012 Oct;10(10):1389-99. doi: 10.1158/1541-7786.MCR-12-0136-T. Epub 2012 Aug 9.

30.

Effects of prior vegetative growth, inoculum density, light, and mating on conidiation of Erysiphe necator.

Gadoury DM, Wakefield LM, Cadle-Davidson L, Dry IB, Seem RC.

Phytopathology. 2012 Jan;102(1):65-72. doi: 10.1094/PHYTO-03-11-0085.

31.

A novel approach for the generation of genetically modified mammary epithelial cell cultures yields new insights into TGFβ signaling in the mammary gland.

Kohn EA, Du Z, Sato M, Van Schyndle CM, Welsh MA, Yang YA, Stuelten CH, Tang B, Ju W, Bottinger EP, Wakefield LM.

Breast Cancer Res. 2010;12(5):R83. doi: 10.1186/bcr2728. Epub 2010 Oct 13.

32.

Modeling metastasis biology and therapy in real time in the mouse lung.

Mendoza A, Hong SH, Osborne T, Khan MA, Campbell K, Briggs J, Eleswarapu A, Buquo L, Ren L, Hewitt SM, Dakir el H, Garfield S, Walker R, Merlino G, Green JE, Hunter KW, Wakefield LM, Khanna C.

J Clin Invest. 2010 Aug;120(8):2979-88. doi: 10.1172/JCI40252. Epub 2010 Jul 19. Erratum in: J Clin Invest. 2010 Oct 1;120(10):3735. Dakir, el-H [corrected to Dakir, El Habib].

33.

Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer.

Stuelten CH, Busch JI, Tang B, Flanders KC, Oshima A, Sutton E, Karpova TS, Roberts AB, Wakefield LM, Niederhuber JE.

PLoS One. 2010 Mar 23;5(3):e9832. doi: 10.1371/journal.pone.0009832.

34.

Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.

Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, Dunn BK, Wakefield LM, Lee MP.

PLoS One. 2010 Feb 15;5(2):e9201. doi: 10.1371/journal.pone.0009201.

35.

Regulation of tumor immune surveillance and tumor immune subversion by tgf-Beta.

Park HY, Wakefield LM, Mamura M.

Immune Netw. 2009 Aug;9(4):122-6. doi: 10.4110/in.2009.9.4.122. Epub 2009 Aug 31.

36.

Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics.

Figueroa JD, Flanders KC, Garcia-Closas M, Anderson WF, Yang XR, Matsuno RK, Duggan MA, Pfeiffer RM, Ooshima A, Cornelison R, Gierach GL, Brinton LA, Lissowska J, Peplonska B, Wakefield LM, Sherman ME.

Breast Cancer Res Treat. 2010 Jun;121(3):727-35. doi: 10.1007/s10549-009-0590-z. Epub 2009 Nov 24.

37.

Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.

Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, Gere S, Kageyama S, Fukuoka J, Nagata T, Tsukada K, Dunn BK, Wakefield LM, Lee MP.

Cancer Res. 2009 Sep 15;69(18):7357-65. doi: 10.1158/0008-5472.CAN-09-0064. Epub 2009 Aug 25.

38.

TGF-beta3 and cancer: a review.

Laverty HG, Wakefield LM, Occleston NL, O'Kane S, Ferguson MW.

Cytokine Growth Factor Rev. 2009 Aug;20(4):305-17. doi: 10.1016/j.cytogfr.2009.07.002. Epub 2009 Aug 4. Review.

PMID:
19656717
39.

Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer.

Kim RJ, Kim SR, Roh KJ, Park SB, Park JR, Kang KS, Kong G, Tang B, Yang YA, Kohn EA, Wakefield LM, Nam JS.

Cancer Lett. 2010 Jan 28;287(2):172-81. doi: 10.1016/j.canlet.2009.06.010. Epub 2009 Jul 7.

PMID:
19586713
40.

Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway.

Bian Y, Terse A, Du J, Hall B, Molinolo A, Zhang P, Chen W, Flanders KC, Gutkind JS, Wakefield LM, Kulkarni AB.

Cancer Res. 2009 Jul 15;69(14):5918-26. doi: 10.1158/0008-5472.CAN-08-4623. Epub 2009 Jul 7.

41.

Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression.

Flanders KC, Wakefield LM.

J Mammary Gland Biol Neoplasia. 2009 Jun;14(2):131-44. doi: 10.1007/s10911-009-9122-z. Epub 2009 Apr 25.

42.

TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression.

di Bari MG, Lutsiak ME, Takai S, Mostböck S, Farsaci B, Semnani RT, Wakefield LM, Schlom J, Sabzevari H.

Cancer Immunol Immunother. 2009 Nov;58(11):1809-18. doi: 10.1007/s00262-009-0692-9. Epub 2009 Mar 25.

43.

Acute wounds accelerate tumorigenesis by a T cell-dependent mechanism.

Stuelten CH, Barbul A, Busch JI, Sutton E, Katz R, Sato M, Wakefield LM, Roberts AB, Niederhuber JE.

Cancer Res. 2008 Sep 15;68(18):7278-82. doi: 10.1158/0008-5472.CAN-08-1842.

44.

Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.

Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM.

Cancer Res. 2008 May 15;68(10):3915-23. doi: 10.1158/0008-5472.CAN-08-0206.

45.

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM.

Cancer Res. 2008 May 15;68(10):3835-43. doi: 10.1158/0008-5472.CAN-08-0215.

46.
47.

Lentiviral reporter constructs for fluorescence tracking of the temporospatial pattern of Smad3 signaling.

Stuelten CH, Kamaraju AK, Wakefield LM, Roberts AB.

Biotechniques. 2007 Sep;43(3):289-90, 292, 294.

48.

Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model.

Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, Du Z, Desprez PY, Anver MR, Michalowska AM, Shih J, Parks WT, Wakefield LM.

Cancer Res. 2007 Sep 15;67(18):8643-52.

49.

Dysadherin: a new player in cancer progression.

Nam JS, Hirohashi S, Wakefield LM.

Cancer Lett. 2007 Oct 8;255(2):161-9. Epub 2007 Apr 17. Review.

50.

Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.

Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC.

Clin Cancer Res. 2007 Apr 1;13(7):2168-77.

Supplemental Content

Loading ...
Support Center